https://www.symmetron.net https://www.symmetron.net/about-us https://www.symmetron.net/careers https://www.symmetron.net/contact https://www.symmetron.net/cookie-policy https://www.symmetron.net/glossary https://www.symmetron.net/media https://www.symmetron.net/old-home https://www.symmetron.net/privacy-policy https://www.symmetron.net/publications https://www.symmetron.net/services https://www.symmetron.net/success-stories https://www.symmetron.net/therapeutic-areas https://www.symmetron.net/sandbox https://www.symmetron.net/services/evidence-development https://www.symmetron.net/services/health-economic-modelling https://www.symmetron.net/services/health-technology-assessment https://www.symmetron.net/services/medical-writing https://www.symmetron.net/services/statistical-analysis https://www.symmetron.net/insights/a-cloud-computing-solution-for-improving-the-run-time-of-individual-patient-simulation-models https://www.symmetron.net/insights/demonstrating-value-real-world-evidence-rwe-in-iras-medicare-drug-price-negotiation https://www.symmetron.net/insights/early-economic-analysis-and-embracing-uncertainty https://www.symmetron.net/insights/early-evidence-generation-a-strategic-roadmap-to-successful-market-access https://www.symmetron.net/insights/early-models-meet-real-world-impact https://www.symmetron.net/insights/evidence-generation-and-communication-in-drug-development https://www.symmetron.net/insights/evidence-synthesis-for-healthcare-decision-making https://www.symmetron.net/insights/from-model-to-interface-a-case-study-on-making-health-economics-accessible-with-r-shiny https://www.symmetron.net/insights/from-model-to-manuscript-five-essential-strategies-for-publishing-health-economic-models https://www.symmetron.net/insights/getting-real-real-world-evidence-in-healthcare https://www.symmetron.net/insights/health-economic-modelling-a-guide-for-pharmaceutical-and-medical-device-companies https://www.symmetron.net/insights/market-access-budget-impact-analysis https://www.symmetron.net/insights/market-access-for-immuno-oncology-i-o-therapies-in-the-uk https://www.symmetron.net/insights/market-access-in-the-eu-helping-you-prepare-for-upcoming-regulatory-changes https://www.symmetron.net/insights/my-summer-internship-at-symmetron https://www.symmetron.net/insights/the-power-of-early-evidence-in-market-access https://www.symmetron.net/insights/unmet-medical-need-and-market-access-enabler-or-barrier-to-innovation https://www.symmetron.net/insights/what-is-qualitative-evidence-synthesis https://www.symmetron.net/insights/when-is-a-simple-model-enough-how-to-handle-structural-uncertainty-in-cost-effectiveness-models https://www.symmetron.net/people/alex-diamantopoulos-msc https://www.symmetron.net/people/anna-pagotto https://www.symmetron.net/people/billy-bryant-msc https://www.symmetron.net/people/bryony-langford https://www.symmetron.net/people/claudia-rinciog-msc https://www.symmetron.net/people/daniela-goncalves-bradley https://www.symmetron.net/people/emily-wright https://www.symmetron.net/people/evangelos-papastergios https://www.symmetron.net/people/frank-grimsey-jones https://www.symmetron.net/people/henna-sharif https://www.symmetron.net/people/joseph-whitaker https://www.symmetron.net/people/kirsten-chalmers https://www.symmetron.net/people/kristen-markus https://www.symmetron.net/people/laura-sawyer https://www.symmetron.net/people/oliver-pople https://www.symmetron.net/people/sam-bryning https://www.symmetron.net/people/samuel-haftel https://www.symmetron.net/people/sarah-cudworth https://www.symmetron.net/people/tanisha-hepworth https://www.symmetron.net/people/veena-lim https://www.symmetron.net/people/vicki-pollit-msc https://www.symmetron.net/people/zara-ishaq https://www.symmetron.net/success-stories/developing-a-framework-for-analysing-the-impact-of-patient-centred-outcomes-for-achieving-reimbursement-in-the-uk https://www.symmetron.net/success-stories/evaluating-the-cost-effectiveness-of-a-diagnostic-device https://www.symmetron.net/success-stories/evaluating-the-cost-effectiveness-of-a-medical-device https://www.symmetron.net/success-stories/gaining-reimbursement-for-a-drug-targeting-a-rare-disease https://www.symmetron.net/success-stories/modelling-survival-after-the-clinical-trials-have-ended https://www.symmetron.net/success-stories/overcoming-limited-evidence-to-gain-reimbursement-for-a-blockbuster-oncology-drug https://www.symmetron.net/success-stories/overcoming-the-short-term-bias-in-clinical-evidence-to-compare-long-term-efficacy-of-psoriasis-treatments https://www.symmetron.net/success-stories/validating-comparisons-of-disease-treatments-in-the-absence-of-head-to-head-trials https://www.symmetron.net/therapeutic-areas/arthritis-and-immunology https://www.symmetron.net/therapeutic-areas/cardiometabolic-health https://www.symmetron.net/therapeutic-areas/dermatology https://www.symmetron.net/therapeutic-areas/neurology-mental-health https://www.symmetron.net/therapeutic-areas/oncology https://www.symmetron.net/therapeutic-areas/policy-and-methods https://www.symmetron.net/therapeutic-areas/rare-diseases https://www.symmetron.net/therapeutic-areas/respiratory https://www.symmetron.net/publication/a-cost-effectiveness-analysis-of-nintedanib-in-idiopathic-pulmonary-fibrosis-in-the-uk https://www.symmetron.net/publication/a-lifetime-modelled-economic-evaluation-comparing-pioglitazone-and-rosiglitazone-for-the-treatment-of-type-2-diabetes-mellitus-in-the-uk https://www.symmetron.net/publication/a-network-meta-analysis-to-evaluate-the-efficacy-of-brodalumab-in-the-treatment-of-moderate-to-severe-psoriasis https://www.symmetron.net/publication/aggregation-kinetics-of-cerium-oxide-nanoparticles-in-monovalent-and-divalent-electrolytes-colloids-and-surfaces-a-physicochemical-and-engineering-aspects https://www.symmetron.net/publication/an-economic-evaluation-of-cetuximab-combined-with-radiotherapy-for-patients-with-locally-advanced-head-and-neck-cancer-in-belgium-france-italy-switzerland-and-the-united-kingdom https://www.symmetron.net/publication/an-economic-evaluation-of-vagus-nerve-stimulation-as-an-adjunctive-treatment-to-anti-seizure-medications-for-the-treatment-of-drug-resistant-epilepsy-in-england https://www.symmetron.net/publication/an-indirect-comparison-via-enoxaparin-of-rivaroxaban-with-dabigatran-in-the-prevention-of-venous-thromboembolism-after-hip-or-knee-replacement https://www.symmetron.net/publication/an-indirect-treatment-comparison-of-cabozantinib-verse-vandetanib-in-progressive-medullary-thyroid-cancer-mtc https://www.symmetron.net/publication/assessing-the-longer-term-efficacy-of-biologic-therapies-and-apremilast-for-patients-with-moderate-to-severe-psoriasis-a-systematic-review-and-network-meta-analysis https://www.symmetron.net/publication/assessing-the-quality-and-coherence-of-network-meta-analyses-of-biologics-in-plaque-psoriasis-what-does-all-this-evidence-synthesis-tell-us https://www.symmetron.net/publication/assessing-the-relative-efficacy-of-interleukin-17-and-interleukin-23-targeted-treatments-for-moderate-to-severe-plaque-psoriasis-a-systematic-review-and-network-meta-analysis-of-pasi-response https://www.symmetron.net/publication/biological-therapies-for-the-treatment-of-severe-psoriasis-in-patients-with-previous-exposure-to-biological-therapy-a-cost-effectiveness-analysis https://www.symmetron.net/publication/conceptualising-global-health-theoretical-issues-and-their-relevance-for-teaching https://www.symmetron.net/publication/cost-and-outcomes-associated-with-rivaroxaban-vs-enoxaparin-for-the-prevention-of-postsurgical-venous-thromboembolism-from-a-us-payers-perspective https://www.symmetron.net/publication/cost-effectiveness-analysis-of-alternative-antiviral-strategies-for-the-treatment-of-hbeag-positive-and-hbeag-negative-chronic-hepatitis-b-in-the-united-kingdom https://www.symmetron.net/publication/cost-effectiveness-analysis-of-nintedanib-versus-pirfenidone-in-idiopathic-pulmonary-fibrosis-in-belgium https://www.symmetron.net/publication/cost-effectiveness-impact-of-rivaroxaban-versus-new-and-existing-prophylaxis-for-the-prevention-of-venous-thromboembolism-after-total-hip-or-knee-replacement-surgery-in-france-italy-and-spain https://www.symmetron.net/publication/cost-effectiveness-of-an-insertable-cardiac-monitor-in-a-high-risk-population-in-the-uk https://www.symmetron.net/publication/cost-effectiveness-of-an-insertable-cardiac-monitor-to-detect-atrial-fibrillation-in-patients-with-cryptogenic-stroke https://www.symmetron.net/publication/cost-effectiveness-of-asenapine-in-the-treatment-of-bipolar-disorder-i-patients-with-mixed-episodes https://www.symmetron.net/publication/cost-effectiveness-of-asenapine-in-the-treatment-of-bipolar-i-disorder-patients-with-mixed-episodes https://www.symmetron.net/publication/cost-effectiveness-of-rivaroxaban-in-the-prevention-of-venous-thromboembolism-a-canadian-analysis-using-the-ontario-ministry-of-health-perspective https://www.symmetron.net/publication/cost-effectiveness-of-rivaroxaban-versus-enoxaparin-for-prevention-of-post-surgical-venous-thromboembolism-from-a-us-payers-perspective https://www.symmetron.net/publication/cost-effectiveness-of-rivaroxaban-versus-enoxaparin-for-the-prevention-of-postsurgical-venous-thromboembolism-in-canada https://www.symmetron.net/publication/cost-effectiveness-of-rivaroxaban-versus-heparins-for-prevention-of-venous-thromboembolism-after-total-hip-or-knee-surgery-in-sweden https://www.symmetron.net/publication/cost-effectiveness-of-vagus-nerve-stimulation-for-treatment-resistant-depression-in-the-united-kingdom https://www.symmetron.net/publication/cost-per-pasi-75-responder-of-calcipotriol-plus-betamethasone-dipropionate-cutaneous-foam-versus-nonbiologic-systemic-therapies-for-the-treatment-of-plaque-psoriasis-in-seven-european-countries https://www.symmetron.net/publication/cost-utility-of-tocilizumab-in-the-treatment-of-systemic-juvenile-idiopathic-arthritis-in-finland https://www.symmetron.net/publication/diagnosis-and-management-of-the-epilepsies-in-adults-and-children-summary-of-updated-nice-guidance https://www.symmetron.net/publication/early-management-of-head-injury-summary-of-updated-nice-guidance https://www.symmetron.net/publication/economic-evaluation-of-tocilizumab-combination-in-the-treatment-of-moderate-to-severe-rheumatoid-arthritis-in-italy https://www.symmetron.net/publication/efficacy-of-novel-dmards-in-early-active-rheumatoid-arthritis-an-indirect-comparison https://www.symmetron.net/publication/evidence-in-support-of-hyperkalaemia-management-strategies-a-systematic-literature-review-international-journal-of-clinical-practice https://www.symmetron.net/publication/exploratory-cost-effectiveness-model-of-electromagnetic-navigation-bronchoscopy-enb-compared-with-ct-guided-biopsy-ttna-for-diagnosis-of-malignant-indeterminate-peripheral-pulmonary-nodules https://www.symmetron.net/publication/exploring-concurrent-validity-of-the-cln2-clinical-rating-scale-comparison-to-pedsql-using-mixed-effects-modelling-and-data-from-a-phase-1-2-single-arm-trial https://www.symmetron.net/publication/focused-ultrasound-thalamotomy-and-other-interventions-for-medication-refractory-essential-tremor-an-indirect-comparison-of-short-term-impact-on-health-related-quality-of-life https://www.symmetron.net/publication/genomic-surveillance-of-methicillin-resistant-staphylococcus-aureus-a-mathematical-early-modelling-study-of-cost-effectiveness https://www.symmetron.net/publication/guideline-development-g-assessment-and-management-of-psoriasis-summary-of-nice-guidance https://www.symmetron.net/publication/guideline-development-g-management-of-bedwetting-in-children-and-young-people-summary-of-nice-guidance https://www.symmetron.net/publication/health-state-utility-values-measured-using-the-euroqol-5-dimensions-questionnaire-in-adults-with-chronic-hepatitis-c-a-systematic-literature-review-and-meta-analysis https://www.symmetron.net/publication/how-do-nice-evidence-review-groups-perceive-single-technology-appraisals-presenting-limited-evidence-of-comparative-treatment-efficacy https://www.symmetron.net/publication/indirect-treatment-comparisons-and-network-meta-analyses-of-naldemedine-for-the-treatment-of-opioid-induced-constipation https://www.symmetron.net/publication/influence-of-salts-and-natural-organic-matter-on-the-stability-of-bacteriophage-ms2 https://www.symmetron.net/publication/long-term-efficacy-of-novel-therapies-in-moderate-to-severe-plaque-psoriasis-a-systematic-review-and-network-meta-analysis-of-pasi-response https://www.symmetron.net/publication/mabthera-rituximab-for-the-treatment-of-severe-granulomatosis-with-polyangiitis-gpa-and-microscopic-polyangiitis-mpa-a-cost-utility-model-for-the-united-kingdom https://www.symmetron.net/publication/management-of-acute-upper-gastrointestinal-bleeding-summary-of-nice-guidance https://www.symmetron.net/publication/pharmacological-interventions-for-familial-hypercholesterolaemia-in-children-and-adolescents-an-exploratory-evaluation-using-advanced-hierarchical-network-meta-analysis-techniques https://www.symmetron.net/publication/severity-score-index-revisited-analysing-the-akussi-and-its-subcomponent-features https://www.symmetron.net/publication/systematic-literature-review-and-network-meta-analysis-of-sglt-2-inhibitors-and-metformin-as-add-on-to-insulin-for-the-treatment-of-type-1-diabetes https://www.symmetron.net/publication/systematic-literature-review-and-network-meta-analysis-of-sodium-glucoses-co-transporter-inhibitors-vs-metformin-as-add-on-to-insulin-in-type-1-diabetes https://www.symmetron.net/publication/targeted-systemic-therapies-for-psoriatic-arthritis-a-systematic-review-and-comparative-synthesis-of-short-term-articular-dermatological-enthesitis-and-dactylitis-outcomes https://www.symmetron.net/publication/targeted-therapies-for-patients-with-moderate-to-severe-psoriasis-a-systematic-review-and-network-meta-analysis-of-pasi-response-at-1-year https://www.symmetron.net/publication/the-burden-of-illness-of-idiopathic-pulmonary-fibrosis-a-comprehensive-evidence-review https://www.symmetron.net/publication/the-cancer-drugs-fund-in-practice-and-under-the-new-framework https://www.symmetron.net/publication/the-challenges-of-outcomes-based-contract-implementation-for-medicines-in-europe https://www.symmetron.net/publication/the-comparative-efficacy-of-brodalumab-in-patients-with-moderate-to-severe-psoriasis-a-systematic-literature-review-and-network-meta-analysis https://www.symmetron.net/publication/the-evolution-of-global-health-teaching-in-undergraduate-medical-curricula https://www.symmetron.net/publication/the-impact-of-patient-reported-outcomes-in-market-access-a-literature-review-regulatory-evidence-assessment-framework-and-study https://www.symmetron.net/publication/tocilizumab-in-methotrexate-naive-rheumatoid-arthritis-a-cost-utility-model-for-slovakia https://www.symmetron.net/publication/tocilizumab-in-polyarticular-juvenile-idiopathic-arthritis-a-cost-utility-model-for-the-united-kingdom https://www.symmetron.net/publication/tocilizumab-in-the-treatment-of-rheumatoid-arthritis-a-cost-effectiveness-analysis-in-the-uk https://www.symmetron.net/publication/tofacitinib-for-the-treatment-of-moderately-to-severely-active-ulcerative-colitis-a-systematic-review-network-meta-analysis-and-economic-evaluation https://www.symmetron.net/publication/topical-therapies-for-the-treatment-of-localized-plaque-psoriasis-in-primary-care-a-cost-effectiveness-analysis-br-j-dermatol https://www.symmetron.net/publication/topical-therapies-for-the-treatment-of-plaque-psoriasis-systematic-review-and-network-meta-analyses https://www.symmetron.net/publication/uk-cost-utility-analysis-of-rituximab-in-patients-with-rheumatoid-arthritis-that-failed-to-respond-adequately-to-a-biologic-disease-modifying-antirheumatic-drug https://www.symmetron.net/publication/using-data-on-survival-with-idiopathic-pulmonary-fibrosis-to-estimate-survival-with-other-types-of-progressive-fibrosis-interstitial-lung-disease-a-bayesian-framework https://www.symmetron.net/publication/validity-of-cost-and-utility-results https://www.symmetron.net/glossary/average-cost https://www.symmetron.net/glossary/cost-benefit-analysis https://www.symmetron.net/glossary/cost-effectiveness-analysis https://www.symmetron.net/glossary/cost-effectiveness-threshold https://www.symmetron.net/glossary/health-economics https://www.symmetron.net/glossary/health-outcome https://www.symmetron.net/glossary/health-state https://www.symmetron.net/glossary/health-technology-assessment https://www.symmetron.net/glossary/healthcare-system https://www.symmetron.net/glossary/incremental-cost https://www.symmetron.net/glossary/incremental-cost-effectiveness-ratio https://www.symmetron.net/glossary/marginal-cost https://www.symmetron.net/glossary/opportunity-cost https://www.symmetron.net/glossary/quality-adjusted-life-years https://www.symmetron.net/glossary/quality-of-life-and-health-related-quality-of-life https://www.symmetron.net/glossary/real-world-evidence https://www.symmetron.net/glossary/total-cost https://www.symmetron.net/glossary/utility